


## **Technology Advisory Committee A Interests Register**


Topic: Risankizumab for previously treated moderately to severely active Crohn's disease [ID3986]

Publication Date: 17/05/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Abdallah Al- Mohammad	Committee member	Financial	Professor Al-Mohammad has received honoraria for lectures from AstraZeneca, Janssen, Takeda and Pharmacosmos, honoraria for attending advisory boards with Novartis, Pharmacosmos and AstraZeneca and he is due to carry out research with Pfizer and possibly with both AstraZeneca and Novartis in 2023. Professor Al-Mohammad confirmed all the above were in cardiology and mainly in heart failure. None of them were related to this appraisal.	N/A	22.11.2022	N/A	It was agreed that his declaration would not prevent Professor Al-Mohammad from participating in discussions on this appraisal.
Becky Pennington	Committee member	Financial	Becky has received payment from Takeda for private consultancy work. Becky confirmed the work was	N/A	24.11.2022	N/A	It was agreed that his declaration would not prevent Becky from participating in



			related to methodological research on the inclusion of carers in economic evaluation and that the work was not specific to any drug and not related to Crohn's.				discussions on this appraisal
Dominic Pivonka	Committee member	Financial	Dominic's employer (AbbVie) is the company sponsor and a possible comparator company.	N/A	25.11.2022 19.02.2023	N/A	As a direct conflict Dominic did not participate in discussions for this appraisal
Dr Mark Samaan	Clinical expert	Financial	Dr Samaan has received advisory board fees from Janssen, Takeda, Sandoz, Samsung, Bioepis, Galapagos and AbbVie, and lecture fees from Bristol-Myers Squibb, Janssen, Takeda, MSD, Falk, AbbVie, and Galapagos.	N/A	16.05.2022 07.03.2023	N/A	It was agreed that his declaration would not prevent Dr Samaan from providing expert advice to the committee
Dr Fiona MacPherson- Smith	Committee Member	Personal interest	Her husband has IBD managed by the NHS and is currently treated with ustekinamab, which has induced remission.	N/A	16.02.2023		It was agreed that her declaration would not prevent Dr Fiona MacPherson-Smith from participating in discussions on this appraisal.



## **GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER**

**Relevant dates:** Detail here the date the interest arose and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.